Search

11. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report

Author(s):

Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Cunningham, Courtney, author
Pearson, Steven D., author
Kazi, Dhruv S., author
Coxson, Pamela G., author
Moran, Andrew E., author
Penko, Joanne, author
Guzman, David, author
Bibbins, Kirsten, author

Publication:

[Boston, MA] : Institute for Clinical and Economic Review, November 24, 2015

Subject(s):

Anticholesteremic Agents -- therapeutic use
Azetidines -- therapeutic use
Enzyme Inhibitors -- therapeutic use
Hypercholesterolemia -- therapy
Hyperlipoproteinemia Type II -- prevention & control
Proprotein Convertases -- economics
Serine Endopeptidases -- economics
New England
United States

12. Integrating behavioral health into primary care: a technology assessment : final report

Author(s):

Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Reed, Sarah Jane, author
Shore, Karen K., author
Weissberg, Jed, author
Pearson, Steven D., author

Publication:

[Boston, MA] : Institute for Clinical and Economic Review, June 2, 2015

Subject(s):

Delivery of Health Care, Integrated -- methods
Delivery of Health Care, Integrated -- organization & administration
Mental Health Services -- organization & administration
Outcome Assessment, Health Care -- organization & administration
Primary Health Care -- organization & administration
Technology Assessment, Biomedical
United States

13. Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks : final report

Author(s):

Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Campbell, Jonathan D., author
Chapman, Rick M., author
Shore, Karen K., author
Weissberg, Jed, author
Whittington, Melanie, author
Pearson, Steven D., author

Publication:

[Boston, MA] : Institute for Clinical and Economic Review, March 14, 2016

Subject(s):

Adrenergic beta-2 Receptor Agonists -- economics
Adrenergic beta-2 Receptor Agonists -- therapeutic use
Anti-Asthmatic Agents -- administration & dosage
Anti-Asthmatic Agents -- economics
Antibodies, Monoclonal, Humanized -- administration & dosage
Antibodies, Monoclonal, Humanized -- economics
Asthma -- drug therapy
Asthma -- immunology
Eosinophilia -- drug therapy
Interleukin-5 -- immunology
United States

14. Insulin degludec (Tresiba®, Novo Nordisk A/S) for the treatment of diabetes: effectiveness, value, and value-based price benchmarks : final report

Author(s):

Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Chapman, Rick M., author
Shore, Karen K., author
Weissberg, Jed, author
Pearson, Steven D., author

Publication:

[Boston, MA] : Institute for Clinical and Economic Review, March 14, 2016

Subject(s):

Blood Glucose -- drug effects
Diabetes Mellitus, Type 1 -- drug therapy
Diabetes Mellitus, Type 2 -- drug therapy
Hypoglycemia -- prevention & control
Hypoglycemic Agents -- therapeutic use
Insulin, Long-Acting -- administration & dosage
Insulin, Long-Acting -- therapeutic use
United States

15. Controversies in migraine management: a technology assessment : final report

Author(s):

Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Weissberg, Jed, author
Shore, Karen K., author
Pearson, Steven D., author

Publication:

[Boston, MA] : Institute for Clinical and Economic Review, August 19, 2014

Subject(s):

Analgesics, Opioid -- therapeutic use
Botulinum Toxins, Type A -- therapeutic use
Emergency Medical Services
Magnetic Field Therapy
Migraine Disorders -- drug therapy
Migraine Disorders -- economics
Migraine Disorders -- prevention & control
Migraine Disorders -- therapy
Transcutaneous Electric Nerve Stimulation
California
United States